| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3283377 | Clinical Gastroenterology and Hepatology | 2012 | 10 Pages |
Abstract
Infliximab was safe and effective, inducing a response at week 8 in 73.3% of pediatric patients with moderate to severely active UC who did not respond to conventional therapy. The overall remission rate at week 54 for all enrolled patients was 28.6%, assuming the more effective q8w remission rate.
Keywords
6-Mercaptopurineevery 8 weeksPUCAI5-ASAAZAMTXIRBACT6-MPazathioprineantinuclear antibody5-Aminosalicylic acidANAInflammatory bowel disease (IBD)tumor necrosis factor alphaintravenous(ly)REACHPediatric Ulcerative Colitis Activity IndexMucosal healingconfidence intervalTNF-αMethotrexateinstitutional review boardClinical trialUlcerative colitis
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jeffrey Hyams, Lakshmi Damaraju, Marion Blank, Jewel Johanns, Cynthia Guzzo, Harland S. Winter, Subra Kugathasan, Stanley Cohen, James Markowitz, Johanna C. Escher, Gigi Veereman-Wauters, Wallace Crandall, Robert Baldassano, Anne Griffiths,